Explore selected human studies by function, studied dose, duration, accompanying ingredients and source. Positive, negative and mixed findings belong in the same review.
Studied doses are not recommended or universally effective doses. Concentration grades do not establish a clinical dose, aglycone basis or equivalence to a study formulation. These selected studies are not a comprehensive or current systematic review.
Source abstracts checked: October 12, 2026 · Coverage: selected studies published 2002–2025
Systematic review / meta-analysis
Menopausal symptoms
Research question & population
Perimenopausal and postmenopausal women; frequency and severity of hot flashes.
Studied daily dose / basis
Median 54 mg/day, expressed as aglycone equivalents across the included trials.
Study duration
6 weeks to 12 months.
Accompanying ingredients / synergy
Extracted or synthesized isoflavones; formulations differed. No general synergy claim is established by this abstract.
Findings & limitations
The pooled analysis reported lower hot-flash frequency and severity than placebo. Substantial heterogeneity, formulation differences and an older evidence base limit generalization; not a claim that all ingredients work.
389 osteopenic postmenopausal women; lumbar-spine and femoral-neck bone mineral density.
Studied daily dose / basis
54 mg/day of genistein; a specific isoflavone, not 54 mg of any mixed extract.
Study duration
24 months.
Accompanying ingredients / synergy
Both genistein and placebo tablets contained calcium and vitamin D. This does not isolate or establish a synergistic effect.
Findings & limitations
Bone mineral density improved in the genistein arm. Fractures were not measured; power for safety was limited. Gastrointestinal side effects and discontinuations were higher in the genistein group.
Women aged 45–60, within five years of menopause; 122 received soy tablets and 126 placebo.
Studied daily dose / basis
200 mg/day of soy isoflavones. The abstract does not establish an aglycone-equivalent reporting basis.
Study duration
2 years.
Accompanying ingredients / synergy
Soy isoflavone tablets versus placebo; accompanying nutrients are not detailed in the indexed abstract.
Findings & limitations
No significant between-group differences in spine, hip or femoral-neck bone loss. Hot flashes and constipation were more frequent in the soy group. A higher studied dose did not establish benefit.
22 young, healthy, normolipidemic adults; HDL and other cardiovascular risk markers.
Studied daily dose / basis
56 versus 2 mg/day of isoflavones within soy-protein diets; not an isolated-extract comparison.
Study duration
17 days per diet, with a 25-day washout.
Accompanying ingredients / synergy
Intact soy protein was the food matrix. The design does not establish synergy or equivalence to a standalone isoflavone ingredient.
Findings & limitations
HDL and apolipoprotein A-I were higher on the high-isoflavone diet; LDL and several other markers were not affected. Small, short study; no evidence of reduced cardiovascular events.
12 eligible studies; pooled symptom outcomes involved different subsets of perimenopausal women.
Studied daily dose / basis
Dose range and reporting basis are not specified in the indexed abstract; review trial-level methods before selecting a dose.
Study duration
Duration range is not specified in the indexed abstract.
Accompanying ingredients / synergy
The indexed abstract does not define a common combination formula or prove ingredient synergy.
Findings & limitations
The review reported a small pooled improvement in overall menopausal symptoms, but no significant effects on hot flushes, sweating, insomnia or vasomotor symptoms. Small samples and differing outcomes limit certainty; contrasts with older hot-flash findings deserve review.
Median reported dose 75 mg/day. The abstract does not establish a uniform aglycone-equivalent basis.
Study duration
Trials of at least 3 months; median 24 weeks.
Accompanying ingredients / synergy
Interventions and non-isoflavone controls differed. No common synergistic combination is established by this abstract.
Findings & limitations
No statistically significant effect on any of the four measures; reported certainty was high to moderate. These endpoints do not demonstrate universal safety or suitability and do not establish equivalence to hormone therapy.
Read both bone studies together: purified genistein and mixed isoflavone tablets are different interventions. The positive result in one trial does not override the negative result in another.
Supporting sources
Summaries are based on the indexed abstracts verified through Europe PMC. Full-text protocols, formulation details and risk of bias require further review. Links identify published research, not studies of SoyOne products.
Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Taku et al. (2012) · PMID 22433977 · DOI 10.1097/gme.0b013e3182410159
Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Marini et al. (2007) · PMID 17577003 · DOI 10.7326/0003-4819-146-12-200706190-00005
Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Levis et al. (2011) · PMID 21824950 · DOI 10.1001/archinternmed.2011.330
Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Sanders et al. (2002) · PMID 12145009 · DOI 10.1093/ajcn/76.2.373
Effects of soy isoflavones on menopausal symptoms in perimenopausal women: a systematic review and meta-analysis. Luan et al. (2025) · PMID 40718787 · DOI 10.7717/peerj.19715
Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Viscardi et al. (2025) · PMID 39433088 · DOI 10.1016/j.advnut.2024.100327
Turn a research question into a formulation brief.
State the population, ingredient composition, reporting basis, dose and duration before considering relevance to a commercial ingredient. Request the specification for your selected grade.
Every two weeks: industry developments and a clear reading of soy isoflavone research. Follow what changed, who was studied, the dose and duration, and what the evidence can support.
